SAM CHUN DANG PHARM CO. LTD Stock Price & Chart

KRX: 000250 · 삼천당제약 · KOSPI

₩149,400 ₩600 (+0.40%)at close · July 27, 2026
1,233,000142,500149,400Jul 03, 25Oct 10Jan 14Apr 20Jul 27, 26

SAM CHUN DANG PHARM CO. LTD (삼천당제약, KRX: 000250) last closed at ₩149,400 on July 27, 2026, a +0.40% move on the day. Over the trailing 52 weeks the stock has traded between ₩142,500 and ₩1,233,000, a -10.00% change over the past year. Figures are end-of-day closing prices from the Korea Exchange.

Last close₩149,400
Day change+0.40%
52-week high₩1,233,000
52-week low₩142,500

Key Fundamentals

FY 2026.03
Market cap₩3.50T
P/E (PER)666.96
P/B (PBR)12.59
EPS₩224
BPS₩11,868
ROE3.65%
Debt ratio45.29%
Rev. growth28.15%

P/E, P/B and market cap are computed from the latest close; EPS, BPS, ROE and debt ratio are the most recent reported figures (FY 2026.03) from the Korea Investment & Securities Open API. Informational only, not investment advice.

Technical Snapshot

as of 2026-07-27
BearishAlgorithmic summary of 5 standard indicators (net score -5). Describes current technical posture only — not a buy or sell recommendation.
  • ▼ Bearish20-day MAPrice below 192,875
  • ▼ Bearish60-day MAPrice below 282,467
  • ▼ Bearish120-day MAPrice below 467,221
  • ▼ BearishMA trend (20 vs 60)Short-term below mid-term
  • · NeutralRSI (14)RSI 38 — neutral zone
  • ▼ BearishMACD (12,26,9)MACD below signal
52-week position: 1% of rangeRSI(14): 385-day volume vs 20-day: +378%

Indicators are computed mechanically from end-of-day prices. They are provided for informational purposes only, are not investment advice or a recommendation, and past performance does not indicate future results.

No daily reports have covered SAM CHUN DANG PHARM CO. LTD yet. New reports appear here automatically when the stock is featured.

← Back to all Korean stocks

Price history is sourced from the Korea Exchange via the Korea Investment & Securities Open API and updated after each trading session. This page is provided for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Data may be delayed or contain errors — verify with an official source before trading.